Search
TOP-1288
go.drugbank.com/drugs/DB14839InvestigationalTOP-1288 is under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis
Lotilaner
go.drugbank.com/drugs/DB17992ApprovedInvestigationalVet approvedLotilaner is an ectoparasiticide that is a member of the isoxazoline family of compounds.
Dinutuximab
go.drugbank.com/drugs/DB09077ApprovedInvestigationalIt is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk … Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse.
Triheptanoin
go.drugbank.com/drugs/DB11677ApprovedInvestigational[A214812,A214817] Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin. … Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation.
Nicoboxil
go.drugbank.com/drugs/DB12911ApprovedWithdrawnNevertheless, it is predominantly found paired with nonivamide as a combination topical analgesic product where its proposed mechanism of action as a rubefacient is complementary and ultimately synergistic
Mixtures: Nonivamid + Nicoboxil Zentiva 4 mg/g + 25 mg/g SalbeSotagliflozin
go.drugbank.com/drugs/DB12713ApprovedInvestigational1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m<sup>2</sup>. … [L39705] Its potency in inhibiting SGLT2 is similar to that of other SGLT2 inhibitors, such as [canagliflozin] and [dapagliflozin], but its potency in inhibiting SGLT1 is >10-fold higher than its predecessors
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersIvosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigationalIvosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. … The drug is only effective in patients with a susceptible IDH1 mutation.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexFamtozinameran
go.drugbank.com/drugs/DB17088ApprovedInvestigationalBA.4, BA.5) which, although similar, may behave differently from one another. … [L43917] Famtozinameran is an mRNA vaccine encoding the S glycoprotein of SARS-CoV-2 Omicron variant lineages BA.4 and BA.5.
Mixtures: Comirnaty Original & Omicron Ba.4/ba.5, Comirnaty Original & Omicron Ba.4/ba.5Revumenib
go.drugbank.com/drugs/DB18515ApprovedInvestigationalAbnormal gene rearrangements at chromosome locus 11q23, called KMT2A rearrangements or translocations, are present in 5%-10% of patients with acute leukemias and are the sole genetic aberration found in … Menin is a scaffold protein that interacts with both the wild-type and rearranged KMT2A, which is crucial for KMT2A activity and the maintenance of _HOXA_ expression and leukemogenesis.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsEstetrol
go.drugbank.com/drugs/DB12235ApprovedInvestigational[L33184] On April 15 2021, Mayne Pharma Group Limited and Mithra Pharmaceuticals were granted FDA approval for the oral contraceptive Estelle/Nextstellis, a combination of [drospirenone] and estetrol … Estetrol is the first new estrogen introduced to the USA in over 50 years and is the first approved estetrol product in the world.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: 15α-hydroxyestriol